Alkermes price target raised to $66 from $60 at Leerink Leerink raised its price target yesterday for shares of Alkermes to $66 after the company reported positive top-line aripiprazole lauroxil Phase III data. The firm expects FDA approval and launch in Q3 of 2015 and reiterates an Outperform rating on the stock.
Alkermes announces FDA approval of ARISTADA Alkermes announced that the U.S. FDA has approved ARISTADA extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA immediately.